Pharmacological management of post-stroke depression

References

• Gorelick PB. The global burden of stroke: persistent and disabling. Lancet Neurol. 2019;18:417–418.
   PubMed Web of Science ®Google Scholar
• GBD 2016 Lifetime Risk of Stroke Collaborators. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N Engl J Med. 2018;379:2429–2437.
   PubMed Web of Science ®Google Scholar
• Hu P, Yang Q, Kong L, et al. Relationship between the anxiety/depression and care burden of the major caregiver of stroke patients. Medicine (Baltimore). 2018;97:e12638.
   PubMed Web of Science ®Google Scholar
• Lackland DT, Roccella EJ, Deutsch AF, et al.; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Council on Functional Genomics and Translational Biology. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke. 2014;45:315–353.
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. Health, United States, 2010: with special features on death and dying. Hyattsville (MD); 2011 [cited 2019 July 1]. Table 31. Available from: http://www.cdc.gov/nchs/hus.htm
   Google Scholar
• Ovbiagele B, Goldstein LB, Higashida RT, et al. Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association. Stroke. 2013;44:2361–2375.
   PubMed Web of Science ®Google Scholar
• Esparrago Llorca G, Castilla-Guerra L, Fernandez Moreno MC, et al. Post-stroke depression: an update. Neurologia. 2015;30:23–31.
   PubMed Web of Science ®Google Scholar
• Angelelli P, Paolucci S, Bivona U, et al. Development of neuropsychiatric symptoms in poststroke patients: a cross-sectional study. Acta Psychiatr Scand. 2004;110:55–63.
   PubMed Web of Science ®Google Scholar
• Dar SK, Venigalla H, Khan AH, et al. Post stroke depression frequently overlooked, undiagnosed, untreated. Neuropsychiatry. 2017;7:906–919.
   Google Scholar
• Taylor-Rowan M, Momoh O, Ayerbe L, et al. Prevalence of pre-stroke depression and its association with post-stroke depression: a systematic review and meta-analysis. Psychol Med. 2019;49:685–696.
   PubMed Web of Science ®Google Scholar
• Pan A, Sun Q, Okereke OI, et al. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA. 2011;306:1241–1249.
   PubMed Web of Science ®Google Scholar
• Hackett ML, Yapa C, Parag V, et al. Frequency of depression after stroke: a systematic review of observational studies. Stroke. 2005;36:1330–1340.
   PubMed Web of Science ®Google Scholar
• Ayerbe L, Ayis S, Wolfe CD, et al. Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. Br J Psychiatry. 2013;202:14–21.
   PubMed Web of Science ®Google Scholar
• Hackett ML, Pickles K. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke. 2014;9:1017–1025.
   PubMed Web of Science ®Google Scholar
• Towfighi A, Ovbiagele B, El Husseini N, et al.; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Poststroke depression: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017;48:e30–e43.
   PubMed Web of Science ®Google Scholar
• Sturm JW, Donnan GA, Dewey HM, et al. Quality of life after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. 2004;35:2340–2345.
   PubMed Web of Science ®Google Scholar
• Pompili M, Venturini P, Campi S, et al. Do stroke patients have an increased risk of developing suicidal ideation or dying by suicide? An overview of the current literature. CNS Neurosci Ther. 2012;18:711–721.
   PubMed Web of Science ®Google Scholar
• Pompili M, Venturini P, Lamis DA, et al. Suicide in stroke survivors: epidemiology and prevention. Drugs Aging. 2015;32:21–29.
   PubMed Web of Science ®Google Scholar
• Cai W, Mueller C, Li YJ, et al. Post stroke depression and risk of stroke recurrence and mortality: a systematic review and meta-analysis. Ageing Res Rev. 2019;50:102–109.
   PubMed Web of Science ®Google Scholar
• Sun Y, Liang Y, Jiao Y, et al. Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis. BMJ Open. 2017;7:e016499.
   PubMed Web of Science ®Google Scholar
• Price A, Rayner L, Okon-Rocha E, et al. Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2011;82:914–923.
   PubMed Web of Science ®Google Scholar
• Carvalho AF, Sharma MS, Brunoni AR, et al. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom. 2016;85:270–288.
   PubMed Web of Science ®Google Scholar
• Elmaadawi A, Singh N, Reddy J. Prescriber’s guide to using 3 new antidepressants. Curr Psychiatry. 2016;14:32–36.
   Google Scholar
• Lipsey JR, Robinson RG, Pearlson GD, et al. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet. 1984;1(8372):297–300.
   PubMed Web of Science ®Google Scholar
• Reding MJ, Orto LA, Winter SW, et al. Antidepressant therapy after stroke: a double-blind trial. Arch Neurol. 1986;43:763–765.
   PubMed Web of Science ®Google Scholar
• Wiart L, Petit H, Joseph P, et al. Fluoxetine in early poststroke depression. Stroke. 2000;31:1829–1832.
   PubMed Web of Science ®Google Scholar
• Fruehwald S, Gatterbauer E, Rehak P, et al. Early fluoxetine treatment of post-stroke depression. J Neurol. 2003;250:347–351.
   PubMed Web of Science ®Google Scholar
• Rampello L, Alvano A, Chiechio S, et al. An evaluation of efficacy and safety of reboxetine in elderly patients affected by “retarded” post-stroke depression: a random, placebo-controlled study. Arch Gerontol Geriatr. 2005;40:275–285.
   PubMed Web of Science ®Google Scholar
• Choi-Kwon S, Han SW, Kwon SU, et al. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness. Stroke. 2006;37:156–161.
   PubMed Web of Science ®Google Scholar
• Li LT, Wang SH, Ge HY, et al. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) and fluoxetine on post-stroke depression. J Altern Complement Med. 2008;14:841–846.
   PubMed Web of Science ®Google Scholar
• Cravello L, Caltagirone C, Spalletta G. The SNRI venlafaxine improves emotional unawareness in patients with post-stroke depression. Hum Psychopharmacol. 2009;4:331–336.
   Google Scholar
• Zhang LS, Hu XY, Yao LY, et al. Prophylactic effects of duloxetine on post-stroke depression symptoms: an open single-blind trial. Eur Neurol. 2013;69:336–343.
   PubMed Web of Science ®Google Scholar
• Yan D, Shan J, Ze Y, et al. The effects of combined hyperbaric oxygen therapy on patients with post-stroke depression. J Phys Ther Sci. 2015;27:1295–1297.
   PubMedGoogle Scholar
• Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke. 1994;25:1099–1104.
   PubMed Web of Science ®Google Scholar
• Hackett ML, Anderson CS, House AO. Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2004;(3):CD003437.
   PubMed Web of Science ®Google Scholar
• Hackett ML, Anderson CS, House A, et al. Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2008;(4):CD003437.
   PubMed Web of Science ®Google Scholar
• Chen Y, Guo JJ, Zhan S, et al. Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis. Ann Pharmacother. 2006;40:2115–2122.
   PubMed Web of Science ®Google Scholar
• Tan S, Huang X, Ding L, et al. Efficacy and safety of citalopram in treating post-stroke depression: a meta-analysis. Eur Neurol. 2015;74:188–201.
   PubMed Web of Science ®Google Scholar
• Xu XM, Zou DZ, Shen LY, et al. Efficacy and feasibility of antidepressant treatment in patients with post-stroke depression. Medicine (Baltimore). 2016;95:e5349.
   PubMed Web of Science ®Google Scholar
• Deng L, Sun X, Qiu S, et al. Interventions for management of post-stroke depression: a Bayesian network meta-analysis of 23 randomized controlled trials. Sci Rep. 2017;7:16466.
   PubMed Web of Science ®Google Scholar
• Starskein SE, Hayhow BD. Treatment of post-stroke depression. Curr Treat Options Neurol. 2019;21:31.
   PubMed Web of Science ®Google Scholar
• Qin B, Chen H, Gao W, et al. Efficacy, acceptability, and tolerability of antidepressant treatments for patients with post-stroke depression: a network meta-analysis. Braz J Med Biol Res. 2018;51:e7218.
   PubMed Web of Science ®Google Scholar
• Cui M, Huang CY, Wang F. Efficacy and safety of citalopram for the treatment of poststroke depression: a meta-analysis. J Stroke Cerebrovasc Dis. 2018;27:2905–2918.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357–1366.
   PubMed Web of Science ®Google Scholar
• Goldstein LB, Lennihan L, Rabadi MJ, et al. Effect of dextroamphetamine on poststroke motor recovery: a randomized clinical trial. JAMA Neurol. 2018;75:1494–1501.
   PubMed Web of Science ®Google Scholar
• Johnson ML, Roberts MD, Ross AR, et al. Methylphenidate in stroke patients with depression. Am J Phys Med Rehabil. 1992;71:239–241.
   PubMed Web of Science ®Google Scholar
• Tarango FE, Allegri R, Vicario A, et al. A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of vascular depression. Int J Geriatr Psychiatry. 2001;16:254–260.
   PubMed Web of Science ®Google Scholar
• Hu Y, Xing H, Dong X, et al. Pioglitazone is an effective treatment for patients with post-stroke depression combined with type 2 diabetes mellitus. Exp Ther Med. 2015;10:1109–1114. [ Epub 2015 Jun 24].
   PubMed Web of Science ®Google Scholar
• Mead G, Hackett ML, Lundström E, et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials. Trials. 2015;16:369.
   PubMedGoogle Scholar
• Shin TK, Kang MS, Lee HY, et al. Fluoxetine and sertraline attenuate postischemic brain injury in mice. Korean J Physiol Pharmacol. 2009;13:257–263.
   PubMed Web of Science ®Google Scholar
• Wang JW, David DJ, Monckton JE, et al. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci. 2008;28:1374–1384.
   PubMed Web of Science ®Google Scholar
• Mikami K, Jorge RE, Adams HP Jr, et al. Effect of antidepressants on the course of disability following stroke. Am J Geriatr Psychiatry. 2011;19:1007–1015.
   Web of Science ®Google Scholar
• Loubinoux I, Boulanouar K, Ranjeva JP, et al. Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. J Cereb Blood Flow Metab. 1999;19:1365–1375.
   PubMed Web of Science ®Google Scholar
• Pariente J, Loubinoux I, Carel C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol. 2001;50:718–729.
   PubMed Web of Science ®Google Scholar
• Acler M, Robol E, Fiaschi A, et al. A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. J Neurol. 2009;256:1152–1158.
   PubMed Web of Science ®Google Scholar
• Chollet F, Tardy J, Albucher JF. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10:123–130.
   PubMed Web of Science ®Google Scholar
• FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet. 2019;393:265–274.
   PubMed Web of Science ®Google Scholar
• Mead GE, Hsieh CF, Lee R. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012;11:CD009286.
   PubMedGoogle Scholar
• Gu SC, Wang CD. Early selective serotonine reuptake inhibitors for recovery after stroke: a meta-analysis and trial sequential analysis. J Stroke Cerebrovasc Dis. 2018;27:1178–1189.
   PubMed Web of Science ®Google Scholar
• van der Worp HB. Fluoxetine and recovery after stroke. Lancet. 2019;393:206–207.
   PubMed Web of Science ®Google Scholar
• Jorge RE, Robinson RG, Arndt S, et al. Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am J Psychiatry. 2003;160:1823–1829.
   PubMed Web of Science ®Google Scholar
• Robinson RG, Jorge RE, Long J. Prevention of poststroke mortality using problem-solving therapy or escitalopram. Am J Geriatr Psychiatry. 2017;25:512–519.
   PubMed Web of Science ®Google Scholar
• Krivoy A, Stubbs B, Balicer RD, et al. Low adherence to antidepressants is associated with increased mortality following stroke: a large nationally representative cohort study. Eur Neuropsychopharmacol. 2017;27:970–976.
   PubMed Web of Science ®Google Scholar
• Robinson RG, Jorge RE, Moser DJ, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA. 2008;299:2391–2400.
   PubMed Web of Science ®Google Scholar
• Chen Y, Patel NC, Guo JJ, et al. Antidepressant prophylaxis for poststroke depression: a meta-analysis. Int Clin Psychopharmacol. 2007;22:159–166.
   PubMed Web of Science ®Google Scholar
• Salter KL, Foley NC, Zhu L, et al. Prevention of poststroke depression: does prophylactic pharmacotherapy work? J Stroke Cerebrovasc Dis. 2013;22:1243–1251.
   PubMed Web of Science ®Google Scholar
• Paolucci S. Advances in antidepressants for treating post-stroke depression. Expert Opin Pharmacother. 2017;18:1011–1017.
   PubMed Web of Science ®Google Scholar
• Villa RF, Ferrari F, Moretti A. Post-stroke depression: mechanisms and pharmacological treatment. Pharmacol Ther. 2018;184:131–144.
   PubMed Web of Science ®Google Scholar
• Levada OA, Troyan AS. Poststroke depression biomarkers: a narrative review. Front Neurol. 2018;9:577.
   PubMed Web of Science ®Google Scholar
• Lee EJ, Oh MS, Kim JS, et al.; EMOTION investigators. Serotonin transporter gene polymorphisms may be associated with poststroke neurological recovery after escitalopram use. J Neurol Neurosurg Psychiatry. 2018;89:271–276.
   PubMed Web of Science ®Google Scholar
• Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157:351–359.
   PubMed Web of Science ®Google Scholar